Bronchoscopic Lung Volume Reduction

Pulmonx Announces Long-Term Follow-Up Data Confirming Significant Benefits of Zephyr Valve for Patients with Severe COPD/Emphysema

Retrieved on: 
Tuesday, July 27, 2021

The improvements from Baseline to 6-months seen in the Zephyr Valve group were maintained out to 12-months.

Key Points: 
  • The improvements from Baseline to 6-months seen in the Zephyr Valve group were maintained out to 12-months.
  • Data for the medically managed control group was only available out to 6-months as these patients opted to have the Zephyr Valve procedure after completing the 6-month evaluation.
  • This is very important data because patients with severe COPD/emphysema have few treatment options once medications no longer alleviate symptoms.
  • The Zephyr Valve is the only endobronchial valve approved for the treatment of this large subset of emphysema patients.

Olympus Makes SeleCT™ QCT Analysis Available Nationwide via the Nuance AI Marketplace to Increase Access to Spiration Valve System Therapy

Retrieved on: 
Tuesday, July 27, 2021

The new service will also provide an option for SeleCT analysis results to be sent to a health system's electronic health record (EHR) for easier referring physician access.

Key Points: 
  • The new service will also provide an option for SeleCT analysis results to be sent to a health system's electronic health record (EHR) for easier referring physician access.
  • "1
    "Our collaboration with Nuance and Olympus advances our mission to add value and help deliver better patient care," said Dave Hannes, CEO, Imbio.
  • For more information on SeleCT Connect or to start using the service, Spiration Valve System customers can contact their Olympus representative.
  • Olympus offers the SeleCT QCT analysis service to evaluate patient eligibility for treatment with the Spiration Valve System, an FDA-designated breakthrough device to treat severe emphysema, a form of chronic obstructive pulmonary disease (COPD).

New Treatment for Severe Emphysema Now Covered Under Medical Mutual of Ohio

Retrieved on: 
Thursday, June 3, 2021

Medical Mutual of Ohio is Ohio's oldest and largest health insurance company with more than 1.5 million covered lives and stands as a local industry leader in developing up-to-date policy guidelines for safe and effective medical technologies.

Key Points: 
  • Medical Mutual of Ohio is Ohio's oldest and largest health insurance company with more than 1.5 million covered lives and stands as a local industry leader in developing up-to-date policy guidelines for safe and effective medical technologies.
  • "This decision by Medical Mutual will provide expanded access to this critical therapy that significantly reduces lung hyperinflation associated with severe emphysema, and is durable over time," said Dr. Jason Stienecker, Division Chief for Pulmonary at Lima Memorial Health System in Lima, Ohio.
  • "Spiration Valve treatment can lead to truly meaningful improvements in patients who achieve sustainable clinical outcomes such as improvements in lung function and quality of life."
  • "Improving lung function in severe heterogenous emphysema with the Spiration Valve System (EMPROVE): a multicenter, open-label, randomized, controlled trial."

Zephyr® Valve Treatment Provides Long-Term Quality of Life and Lung Function Improvements for Patients with Severe COPD/Emphysema

Retrieved on: 
Monday, May 17, 2021

The new data confirm the long-term benefits of the Zephyr\xc2\xae Endobronchial Valve (Zephyr Valve), the first minimally invasive procedure to treat patients with severe COPD/emphysema.

Key Points: 
  • The new data confirm the long-term benefits of the Zephyr\xc2\xae Endobronchial Valve (Zephyr Valve), the first minimally invasive procedure to treat patients with severe COPD/emphysema.
  • \xe2\x80\x9cThus, these long-term data further demonstrate that our Zephyr Valve is a safe, effective, and lasting treatment option for patients with severe COPD/emphysema.\xe2\x80\x9d\nThe virtual presentation entitled \xe2\x80\x9cLong-Term Follow-up of Severe Emphysema Patients Treated with Zephyr Valves in the Multicenter, Randomized TRANSFORM Study\xe2\x80\x9d was presented by D.J.
  • Patients were randomized to treatment with 65 receiving the Zephyr Endobronchial Valves and 32 patients randomized to standard of care (optimal medical management).
  • Zephyr valve treated patients were followed out to 24-months with evaluations at 12-, 18-, and 24-months.

Over 20,000 Patients Treated with the Non-Surgical Zephyr Valve for Severe Emphysema, a Form of COPD

Retrieved on: 
Monday, November 30, 2020

REDWOOD CITY, Calif., Nov. 30, 2020 (GLOBE NEWSWIRE) -- As part of COPD Awareness Month, Pulmonx Corporation is announcing that over 20,000 patients have been treated worldwide with their Zephyr Endobronchial Valves (Zephyr Valve), the first FDA-approved minimally-invasive treatment for severe emphysema, a form of COPD.

Key Points: 
  • REDWOOD CITY, Calif., Nov. 30, 2020 (GLOBE NEWSWIRE) -- As part of COPD Awareness Month, Pulmonx Corporation is announcing that over 20,000 patients have been treated worldwide with their Zephyr Endobronchial Valves (Zephyr Valve), the first FDA-approved minimally-invasive treatment for severe emphysema, a form of COPD.
  • The Zephyr Valve is quickly becoming a standard of care for patients with advanced COPD/emphysema.
  • Pulmonx Corporation (NASDAQ: LUNG) is a commercial-stage medical technology company that provides minimally invasive treatment for patients with severe emphysema, a form of COPD.
  • The Zephyr Valve is commercially available in more than 25 countries, with over 80,000 valves used to treat more than 20,000 patients.

Health Care Service Corporation (HCSC) Adds Coverage Policy for Severe Emphysema Treatment

Retrieved on: 
Wednesday, November 18, 2020

CENTER VALLEY, Pa., Nov. 18, 2020 /PRNewswire/ --Olympus announced that Health Care Service Corporation (HCSC) updated their coverage policy to include the Spiration Valve System for eligible patients suffering from severe emphysema, a form of COPD (Chronic Obstructive Pulmonary Disease).

Key Points: 
  • CENTER VALLEY, Pa., Nov. 18, 2020 /PRNewswire/ --Olympus announced that Health Care Service Corporation (HCSC) updated their coverage policy to include the Spiration Valve System for eligible patients suffering from severe emphysema, a form of COPD (Chronic Obstructive Pulmonary Disease).
  • This new coverage provides a minimally invasive treatment alternative for eligible patients.
  • The effective date of the policy covering the Spiration Valves was November 1, 2020.
  • "This expanded coverage for endobronchial valve treatment is great news for patients who suffer from the debilitating symptoms of severe emphysema," said Dr. David Mason of Baylor University Medical Center in Dallas, Texas.

Olympus Celebrates Spiration Valve 500-Patient Milestone with Social Media Presence for the Patient Community

Retrieved on: 
Monday, November 16, 2020

This social media presence is designed to improve patient education and community-building activities around the important valve procedure option for patients with severe emphysema, the most severe form of Chronic Obstructive Pulmonary Disease (COPD).

Key Points: 
  • This social media presence is designed to improve patient education and community-building activities around the important valve procedure option for patients with severe emphysema, the most severe form of Chronic Obstructive Pulmonary Disease (COPD).
  • Chris, a Spiration Valve System patient
    "We are so proud to connect with patients who are hoping for improved quality of life.
  • Connect with more patients: Patients can connect with one another on the official patient-advocacy Spiration Valve System Facebook page: https://www.facebook.com/SpirationValve .
  • Physicians interested in the Spiration Valve System should contact their Olympus sales representative, or Olympus customer service at 1-800-848-9024.

Pulmonx Announces Additional 16 Million Covered Lives for The Zephyr® Valve, a Minimally Invasive Treatment Option for Severe Emphysema (COPD)

Retrieved on: 
Monday, November 2, 2020

As a pulmonologist in Illinois I am very excited to see the Zephyr Valve covered by these Blue Cross Blue Shield plans.

Key Points: 
  • As a pulmonologist in Illinois I am very excited to see the Zephyr Valve covered by these Blue Cross Blue Shield plans.
  • Having this minimally invasive option covered by the largest insurer in the state means we can help more patients breathe easier once medications no longer control their disease well.
  • The Zephyr Valve is a minimally invasive treatment option for severe emphysema, a form of COPD.
  • Pulmonx Corporation (NASDAQ: LUNG) is a commercial-stage medical technology company that provides minimally invasive treatment for patients with severe emphysema, a form of COPD.